攀登 RAS，癌基因的珠穆朗玛峰。
Climbing RAS, the everest of oncogenes.
机构信息
1University of Turin, Department of Oncology, Candiolo (TO); 2IRCC, Institute for Cancer Research and Treatment at Candiolo, Candiolo (TO); 3FIRC Institute of Molecular Oncology (IFOM), Milan, Italy.
出版信息
Cancer Discov. 2014 Jan;4(1):19-21. doi: 10.1158/2159-8290.CD-13-0906.
PMID:24402942
Abstract
Mutations that activate the small GTP-binding protein KRAS are the most common oncogenic event in human tumors. Thirty years after its discovery, mutant KRAS has yet to be therapeutically conquered.
摘要
激活小分子 G 蛋白 KRAS 的突变是人类肿瘤中最常见的致癌事件。在发现 KRAS 突变 30 年后，仍然没有有效的治疗方法来攻克 KRAS 突变。
Zotero 插件